Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.
about
Diarrheagenic Escherichia coliThe bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.Interactions of Shiga-like toxin with human peripheral blood monocytes.Shiga toxin pathogenesis: kidney complications and renal failure.Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice.Oral administration of Shiga toxin-producing Escherichia coli induces intestinal and systemic specific immune response in mice.Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.Comparison of the relative toxicities of Shiga-like toxins type I and type II for miceInduction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramidePurified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages.Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines.Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization.Immune response to verotoxin 1 and 2 in children with Escherichia coli O157:H7 hemorrhagic colitis and classic hemolytic uremic syndrome.CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety?Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.Apoptosis in acute shigellosis is associated with increased production of Fas/Fas ligand, perforin, caspase-1, and caspase-3 but reduced production of Bcl-2 and interleukin-2.Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1.Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis.Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.Comparative susceptibility of B cells with different lineages to cytotoxicity and apoptosis induction by translational inhibitors.Anti-Shiga toxin immunoglobulin G antibodies in healthy South Korean slaughterhouse workers.
P2860
Q24533466-32D50CDF-E87A-420A-AFFF-D1190572A744Q24563989-049D93C3-7A12-4478-BE6E-BABC57F0BB25Q30418998-C5A686C2-616C-4E3B-A26D-6A1319394815Q33337454-130BC222-9235-490E-9014-C9CED9DFD295Q33375578-37C2A6F1-B4E4-49EB-8AEC-BC44D4CE3B5FQ33397541-CAED1FB4-64FD-409E-ACCC-E66175FFD31DQ33401560-349C228E-FB78-4EC8-A9B4-E7AFA3F036A0Q33412526-B7ABB731-8C3F-493B-B756-12723A7FB5F2Q33492004-16EFE0AD-D422-48E6-B81D-50C9AC53DE76Q33498518-20040C26-AD1A-4C50-860B-9C1D753C6715Q33605233-774257B8-B351-4438-9B5F-53BBFB3391D8Q33837961-36D6C30C-FC63-49AE-A099-B73CF29AD34CQ34545284-CF60B6CA-67B7-4C36-A54D-C029FBD97792Q35480200-123D8B2B-08E6-40F9-8BF0-A0D5828AF3A6Q35550028-69AA9A98-3F10-46F2-BC32-9FB02CC5BA8AQ35892930-803859EE-37B3-47BA-AE91-57B16A3FA65CQ36363421-61A8607B-5088-41AA-9613-01E20E068691Q38022246-A300FBA8-9240-473F-A67C-603244DD45C6Q39432827-B86A7955-E72D-459B-8812-7901CAF01216Q39610465-459F33C8-5E00-40B2-9802-ADB63CBECD33Q39655200-17D27AC1-E961-43D6-A90E-3146BFED7B39Q40186741-C863EC11-3074-4685-8D5D-445623BBF265Q40203480-12278974-6416-4E7E-9608-3DE256B24DD8Q40609398-47E30936-A3A4-49C6-9725-43C83A8654BAQ41993044-ADB0A44A-C4B8-4732-B89D-B59E8609015AQ44718291-7B122D0F-ED39-4EC8-8634-4EBF93E6D92AQ53399057-FF0EE782-3294-497A-B4A5-073B3CF21278
P2860
Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Expression of glycolipid recep ...... esponse to dysenteric disease.
@ast
Expression of glycolipid recep ...... esponse to dysenteric disease.
@en
type
label
Expression of glycolipid recep ...... esponse to dysenteric disease.
@ast
Expression of glycolipid recep ...... esponse to dysenteric disease.
@en
prefLabel
Expression of glycolipid recep ...... esponse to dysenteric disease.
@ast
Expression of glycolipid recep ...... esponse to dysenteric disease.
@en
P2093
P356
P1476
Expression of glycolipid recep ...... esponse to dysenteric disease.
@en
P2093
Freedman MH
Lingwood CA
Madrid-Marina V
P356
10.1093/INTIMM/2.1.1
P577
1990-01-01T00:00:00Z